Agios Pharmaceuticals, Inc.
AGIO Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$36.85
KIRA · Stoqly’s AI analyst, in plain words
- Agios Pharmaceuticals, Inc. had $54.0M of revenue in fiscal 2025, up 48.0% on the year before.
- Its operating margin was −873.9%, up 292.6 pts: of every 100 in sales, about −874 is left after running the business.
- Agios Pharmaceuticals, Inc. lost $413M in fiscal 2025.
- Free cash flow was −$377M in fiscal 2025, −698.3% of revenue.
Market cap
$2.2B
P/E
—
Revenue
$54.0M
Net income
−$413M
Free cash flow
−$377M
Operating margin
−873.9%
Agios Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+48.0%
Yes. Sales grew 48.0% last year.
Does it make a profit?
−764.0%
No. It lost money last year.
Does profit turn into cash?
−698.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Agios Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 12, 2026
- Legal name
- AGIOS PHARMACEUTICALS, INC.
- CIK
- 0001439222
Agios Pharmaceuticals, Inc. · AGIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $14.2M | $26.8M | $36.5M | $54.0M |
| Revenue growth | — | — | 88.4% | 36.1% | 48.0% |
| Gross margin | — | 88.0% | 89.3% | 88.6% | 88.3% |
| Operating margin | — | −2,732.1% | −1,459.5% | −1,166.5% | −873.9% |
| Net income | $1.6B | −$232M | −$352M | $674M | −$413M |
| Net margin | — | −1,627.8% | −1,312.6% | 1,845.9% | −764.0% |
| Diluted EPS | $26.55 | −$4.23 | −$6.33 | $11.64 | −$7.12 |
| Cash | |||||
| Cash from operations | −$407M | −$309M | −$296M | −$390M | −$373M |
| Capital expenditure | $5.7M | $4.9M | $1.0M | $1.7M | $4.3M |
| Free cash flow | −$413M | −$314M | −$297M | −$392M | −$377M |
| FCF margin | — | −2,207.6% | −1,107.5% | −1,072.7% | −698.3% |
| Share count change | −12.4% | −9.4% | 1.6% | 4.0% | 0.1% |
| Debt and strength | |||||
| Cash and short-term investments | $1.0B | $783M | $777M | $894M | $854M |
| Shareholders' equity | $1.3B | $1.1B | $811M | $1.5B | $1.2B |
| Current ratio | 17.8x | 13.3x | 12.3x | 11.9x | 11.5x |
| Returns and quality | |||||
| Return on equity | 189.7% | −19.4% | −36.8% | 57.3% | −30.2% |
| Return on tangible equity | 124.2% | −21.1% | −43.4% | 43.7% | −34.6% |
| Piotroski F-score | 4 | 2 | 3 | 2 | 2 |
| Altman Z'' | 11.6 | 9.1 | 6.4 | 14.7 | 12.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$4.6M
8 insiders
Of sales under plans
97%
$4.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Agios Pharmaceuticals, Inc. · AGIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $36.85 a share, the company is worth $2.2B.
Source: SEC EDGAR XBRL filings (CIK 0001439222). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.